贝伐珠单抗联合腹腔热灌注化疗对卵巢癌患者APE1/Ref-1基因表达的影响

目的]探讨贝伐珠单抗联合腹腔热灌注化疗治疗卵巢癌患者的疗效及对APE1/Ref-1基因表达的影响.方法]取卵巢癌患者80例,根据治疗方法不同分为对照组和观察组,每组40例.两组患者均给予紫杉醇联合卡铂化疗,对照组采用腹腔热灌注化疗治疗,观察组在对照组基础上联合腹腔内贝伐珠单抗治疗,比较两组临床疗效及对APE1/Ref-1基因表达的影响.结果]观察组有效率为90.00％(36/40),明显高于对照组67.50％(27/40),其差异有统计学意义(P＜0.05);观察组患者治疗4周后不良反应发生率为15.00％(6/40),与对照组17.50％(7/40)比较差异无统计学意义(P＞0.05);Western blot结果显示:观察组治疗后APE1/Rcf-1基因表达量显著增高,显著高于对照组APE1/Ref-1基因表达量(P＜0.05).结论]贝伐珠单抗合并用于腹腔热灌注化疗治疗卵巢癌患者,疗效满意,治疗时APE1/Ref-1基因表达明显增强,有助于提高化疗敏感性,值得推广应用.

Effect of Intraperitoneal Bevacizumab Combined with Intraperitoneal Hyperthermic Perfusion Chemotherapy on APE1 / Ref-1 Gene Expression in Ovarian Cancer Patients

Objective]To explore the application of intraperitoneal bevacizumab (abdominal Neibeifazhu monoclonal antibody) combined with intraperitoneal hyperthermic perfusion chemotherapy in ovarian cancer patients and to detect the changes of APE1/Ref-1 gene expression before and after the treatment.Methods]Eighty cases of ovarian cancer were randomly divided into control group (n =40) and observation group (n =40).Two groups of patients were treated with paclitaxel and carboplatin chemotherapy.Patients in the control group received intraperitoneal hyperthermic perfusion chemotherapy treatment,and patients in the observation group received intraperitoneal hyperthermic perfusion chemotherapy combined with intraperitoneal bevacizumab (Neibeifazhu monoclonal antibody).The clinical efficacy and APE1/Ref-1 gene expression were compared between the two groups.Results]After 4 weeks of treatment,the curative effect of the observation group was 90％,which was higher than that of the control group (67.50％),and the difference was significant (P ＜0.05).The adverse reaction rate had no significant difference between the observation group (6/40,15 ％) and control group(7/40,17.5 ％) (P ＞0.05).Real time PCR showed that APE1/Ref-1 gene expression was significantly increased after treatment in the two groups compared to that before treatment.The changes of APE-1/Reb1 expression level in the observation group was significantly higher than that in the control group (P ＜0.05).Conclusion]Compared to intraperitoneal hyperthermic perfusion alone,the clinical effect of bevacizumab combined with intraperitoneal hyperthermic perfusion chemotherapy in ovarian cancer patients is better.During this combo treatment,APE1/Reef-1 gene expression was significantly enhanced in ovarian cancer tissues to improve the sensitivity to chemotherapy.It is worthy of popularization and application.